Liisa Bayko
Stock Analyst at Evercore ISI Group
(2.73)
# 616
Out of 5,372 analysts
92
Total ratings
56.06%
Success rate
35.85%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
SVRA Savara | Maintains: In-Line | 3 2 | 2.07 | -3.38% | 4 | May 28, 2025 | |
CRSP CRISPR Therapeutics | Upgrades: Outperform | 60 99 | 42.93 | 130.61% | 2 | Feb 14, 2025 | |
TVTX Travere Therapeutics | Maintains: Outperform | 33 45 | 14.16 | 217.8% | 5 | Feb 12, 2025 | |
BCRX BioCryst Pharma | Maintains: Outperform | 10 12 | 10.04 | 19.52% | 5 | Jan 13, 2025 | |
EDIT Editas Medicine | Maintains: Outperform | 7 5 | 2.19 | 128.31% | 5 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 4 1 | n/a | n/a | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 35 | 27.74 | 26.17% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 405 360 | 278.17 | 29.42% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 438 515 | 443.8 | 16.04% | 16 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 210 260 | 306.21 | -15.09% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 945 70 | n/a | n/a | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: In-Line | 7 2 | 1.15 | 73.91% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 37 33 | 9.79 | 237.08% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 50 38 | 54.79 | -30.64% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 60 80 | 36.44 | 119.54% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 18 | 5.62 | 220.28% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 14 25 | 6.73 | 271.47% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 62 | 7.05 | 779.43% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 35 | 6.09 | 474.71% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 24 | 20.98 | 14.39% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 378 | n/a | n/a | 1 | Mar 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Outperform | 30 | 10.61 | 182.75% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Market Outperform | 10 | 3.48 | 187.36% | 1 | Feb 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Market Outperform | 175 | n/a | n/a | 3 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Outperform | 10 16 | n/a | n/a | 1 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 20 | n/a | n/a | 1 | May 19, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 1 | Jan 31, 2017 |